Search research articles
Contact Us
Filters
Showing results (81-90 of 119) with videos related to
Page
of 12
Sort By:
Scientific Reports
|
February 15, 2019
Ambient and controlled exposures to particulate air pollution and acute changes in heart rate variability and repolarization
Susanne Breitner, Annette Peters, Wojciech Zareba, et al.
Environmental Research
|
May 14, 2016
Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation?
Meng Wang, Mark J Utell, Alexandra Schneider, et al.
Research Report (Health Effects Institute)
|
June 30, 2017
Ambient and Controlled Particle Exposures as Triggers for Acute ECG Changes
David Q Rich, Annette Peters, Alexandra Schneider, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 23, 2013
Caffeine consumption and risk of dyskinesia in CALM-PD
Anne-Marie A Wills, Shirley Eberly, Marsha Tennis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 15, 2012
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease
Bernard Ravina, Kenneth Marek, Shirley Eberly, et al.
Archives of Neurology
|
February 16, 2006
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
Karen Blindauer, Ira Shoulson, David Oakes, et al.
Archives of Neurology
|
June 14, 2006
Preparing for preventive clinical trials: the Predict-HD study
Jane S Paulsen, Michael Hayden, Julie C Stout, et al.
Clinical Parkinsonism & Related Disorders
|
December 4, 2023
Internal tremor in people with Parkinson's Disease: Demographic characteristics and comorbid symptoms
Lana M Chahine, Lakshmi Arbatti, Abhishek Hosamath, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Nature Medicine
|
August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 119) with videos related to
Sort By:
Page
of 12
Scientific Reports
|
February 15, 2019
Ambient and controlled exposures to particulate air pollution and acute changes in heart rate variability and repolarization
Susanne Breitner, Annette Peters, Wojciech Zareba, et al.
Environmental Research
|
May 14, 2016
Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation?
Meng Wang, Mark J Utell, Alexandra Schneider, et al.
Research Report (Health Effects Institute)
|
June 30, 2017
Ambient and Controlled Particle Exposures as Triggers for Acute ECG Changes
David Q Rich, Annette Peters, Alexandra Schneider, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 23, 2013
Caffeine consumption and risk of dyskinesia in CALM-PD
Anne-Marie A Wills, Shirley Eberly, Marsha Tennis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 15, 2012
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease
Bernard Ravina, Kenneth Marek, Shirley Eberly, et al.
Archives of Neurology
|
February 16, 2006
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
Karen Blindauer, Ira Shoulson, David Oakes, et al.
Archives of Neurology
|
June 14, 2006
Preparing for preventive clinical trials: the Predict-HD study
Jane S Paulsen, Michael Hayden, Julie C Stout, et al.
Clinical Parkinsonism & Related Disorders
|
December 4, 2023
Internal tremor in people with Parkinson's Disease: Demographic characteristics and comorbid symptoms
Lana M Chahine, Lakshmi Arbatti, Abhishek Hosamath, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Nature Medicine
|
August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Page
of 12